cyrilzakka/clinical-trials huggingface dataset:
Pattern and Surgical Treatment of Parotid Gland Neoplasms

in these study we analyze pattern of parotid gland neoplasms according to histopathological types, most common type clinical presentation and type of surgical treatment(superficial parotidectomy or total parotidectomy radical parotidectomy

aim of study is to analyze pattern of parotid glands neoplasms in upper Egypt as regard

1)age 2) sex , 3) clinical presentation :symptom (parotid lump, pain and facial nerve paralysis) and sign (tenderness, fixation of parotid lump and presence of lymph nodes) 4)histopathological types:(benign or malignant 5)surgical options :superficial parotidectomy, total parotidectomy or radical parotidectomy 6)postoperative complications :facial nerve dysfunction, fistula ,recurrence 7) mortality rate all data will be recorded, tabulated , and statistically analyzed .

Eligibility Criteria:
Inclusion Criteria:

* all patient with parotid neoplasm with any age and sex at the period between may2015 to May2021 presented in upper Egypt enrolled in this study all the data will recorded ,tabulated and statistically analyzed emphasizing on:

  1) age. 2)sex. 3)clinical presentation: symptoms (parotid lump ,pain and facial nerve paralysis
  * sign (tenderness ,fixations of parotid lump and presence of lymph nodes) . 4)surgical options : - superficial parotidectomy (partial superficial parotidectomy or formal superficial parotidectomy) .
* total parotidectomy .
* radical parotidectomy. 5)postoperative complications: facial nerve dysfunction, fistula , recurrence) .

  6) mortality rate.

Exclusion criteria:

No exclusion criteria
Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale

Migraine attack is an episodic disorder that affects approximately 12% of the population. Previous studies have shown that 41-48% of migraineur have a combination of patent foramen ovale (PFO). Clinical observational studies have been linking medication therapies which include anticoagulation and anti-platelet therapy with the effectiveness in improving migraine symptoms and reducing the frequency of attacks in patients combined with a PFO. However, it has been unclear whether the effectiveness of anticoagulation or anti-platelet therapy outweigh the conventional migraine medication therapy, as a result, we designed a multi-center randomized clinical trial aiming to examine the effectiveness of anticoagulation versus anti-platelet versus migraine medication therapy in migraine patients with PFO and provide a clinical guidance for migraineur.


Eligibility Criteria:
Inclusion Criteria:

1. Age 18-65 ；
2. Diagnosed migraine by ICHD-3
3. History of migraine longer than 1 year
4. TCD/TTE/TEE diagnosed patent foramen ovale
5. Willing to participant and agree to follow-ups

Exclusion Criteria:

1. Migraine caused by other reason
2. Had TIA/stroke history
3. Hypersensitive or hyposensitive to the study drug
4. With a history of anticoagulation or anti-platelet drug intake 3 month before randomization.
5. With a history of metoprolol intake 3 month before randomization, and migraine attacks did not reduced 50%.
A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.

This randomized, 2 x 2 factorial, parrallel group study will compare the efficacy and safety of 48 versus 96 weeks of peginterferon alfa-2a \[Pegasys\], with or without entecavir, in patients with HbeAg negative chronic hepatitis B. Patients will be randomly allocated to receive Pegasys (180mcg subcutaneously weekly) for 48 weeks plus placebo (group A) or entecavir (0,5mg orally daily, group B) during weeks 12-36, or Pegasys (180mcg subcutaneously weekly) for 96 weeks plus placebo (group C) or entecavir (group D) during weeks 12-36. Anticipated time on study treatment is 48 or 96 weeks, with a follow-up of 48 weeks. Target sample size is \<500 patients.


Eligibility Criteria:
Inclusion Criteria:

* adult patients, \>/= 18 years of age
* chronic hepatitis B for \>/= 6 months
* HBeAg negative at screening
* adequate renal function

Exclusion Criteria:

* antiviral therapy for chronic hepatitis B within the previous 6 months
* hepatitis A, C, D or HIV infection
* treatment with systemic acyclovir or famciclovir within the previous 6 months
* decompensated liver disease (Childs B-C)
* history or evidence of a medical condition associated with chronic liver disease
Efficacy of Voluven® for the Prevention of Hypotension During Spinal Anesthesia for Cesarean Section

The aim of the study is to evaluate the efficacy of Voluven® in the prevention of maternal hypotension in women undergoing spinal anesthesia for cesarean section

Intravenous fluid administration prior to spinal anesthesia for cesarean section is an established part of anesthetic practice for the prevention of maternal hypotension. Systematic reviews of clinical data suggest the usefulness of administering colloids to decrease the incidence of hypotension This study will compare the clinical efficacy and safety of HES 130/0.4 (6%) in normal saline vs. Ringer's lactate solution in prevention of hypotension during spinal anesthesia for elective cesarean section.

Eligibility Criteria:
Inclusion Criteria:

* elective cesarean section applying spinal anesthesia
* ≥ week 37 of gestation
* Singleton pregnancy

Exclusion Criteria:

* Suspicion of any hypertensive disease
* Parturient in labor
Action Observation and Motor Imagery Therapy in Stroke

In recent years, motor imagery (MI) and action observation (AO) therapy strategies have been used in rehabilitation programs to increase motor learning in stroke. Visuomotor training strategies such as AO and MI therapy rely on the activity of the mirror neuron system to facilitate motor re-learning. Mirror neurons are activated during the performance of goal-directed actions, also when observing the same action and visualizing the action in the mind.

This clinical trial aims to test whether the application of AO and MI treatment in stroke in addition to conventional rehabilitation programs has an additional effect on motor recovery, activities of daily living, and quality of life.

Stroke is one of the most common neurological disorders that causes chronic disability in adulthood. Stroke-related neurological dysfunction causes impairment in motor and sensory skills and limitation in the ability to perform daily living activities, resulting in decreased independence of patients. This process causes significant impairment in the quality of life of stroke patients.

In recent years, motor imagery (MI) and action observation (AO) therapy strategies have been used in rehabilitation programs to increase motor learning in stroke. Visuomotor training strategies such as AO and MI therapy rely on the activity of the mirror neuron system to facilitate motor re-learning. Mirror neurons are activated during the performance of goal-directed actions, also when observing the same action and visualizing the action in the mind.

This clinical trial aims to test whether the application of AO and MI treatment in stroke in addition to conventional rehabilitation programs has an additional effect on motor recovery, activities of daily living, and quality of life.

Eligibility Criteria:
Inclusion Criteria:

* Patients who had a stroke in the last year
* Functional Ambulation Classification score 2-5

Exclusion Criteria:

* Patients who have had repeated strokes
* Patients with neglect
* Patients with cognitive dysfunction (those who cannot follow simple verbal instructions)
* Patients with severe hearing problems
* Patients with severe vision problems
* Patients with additional musculoskeletal system pathology that will affect physical performance (such as amputation, severe joint mobility limitation, peripheral nerve damage)
* Patients with uncontrolled hypertension and diabetes mellitus
* Patients with a history of symptomatic lung disease (such as asthma, chronic obstructive pulmonary disease, emphysema)
* Patients with a history of symptomatic cardiac disease (such as coronary artery disease, arrhythmia, heart failure)
* Patients with peripheral artery disease
Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis

To assess the efficacy of Locobase REPAIR® when used in children with moderate to severe AD


Eligibility Criteria:
Inclusion Criteria:

* Has given written informed consent (parents or guardian, child if applicable)
* Moderate to severe AD
* Continuous use of topical corticosteroid or topical calcineurin inhibitor (TCI) as active treatment of AD for more than 4 weeks prior to screening (no change in topical corticosteroid or TCI is allowed between screening and day 1)
* In the opinion of the investigator, subject is unlikely to require a significant change to his/her current treatment regimen during the study period

Exclusion Criteria:

* Has infected lesions
* The last assessment of any clinical study within 3 months prior to the expected date of entering into the study
* Current use of Locobase® REPAIR
* Known allergy to Locobase® REPAIR or any of its components
* Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the study
Brain Activity in Adults With ADHD During Neuropsychological Tasks

The aim of the study is to investigate the response on cognitive testing of healthy persons compared to adults with or without medication against ADHD.

Attention Deficit Hyperactivity Disorder (ADHD) is one of the most prevalent psychiatric disorders in children and adolescents. It is characterized by inattentive, hyperactive, impulsive behaviour and neuropsychological deficits. In 40-60% of cases emerge in childhood and persists into adulthood.

The aim of the study is to investigate the response on cognitive testing of healthy persons compared to adults with or without medication against ADHD. As a secondary endpoint a more robust diagnosing method combining advanced imaging methods with neuropsychological evaluation is tested.

Neuropsychological testing, functional MRI and spectroscopy will be performed. Statistical analysis will assess differences in the functional magnetic resonance imaging, spectroscopy and neuropsychological evaluation results between three groups: 1) group of healthy volunteers, 2) participants with ADHD with medication and 3) participants with ADHD without medication.

Eligibility Criteria:
Inclusion Criteria:

* Participant is between 20-55 years old
* Participant is not pregnant

Exclusion Criteria:

* Participant is not able to consent him/herself
* Suspected or proven pregnancy
* Nursing
* Neurological diseases that could interfere with a diagnosis of ADHD
* Psychiatric comorbidity under treatment
* Previous history of psychiatric medication
* Substance abuse
* Intelligence quotient\<75
* Claustrophobia
* Electrical simulator nerve or bone
* Implanted medication infusion pump
* Cerebral aneurysm clips
* Unstable medical condition
The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis

Some people with nasal allergy symptoms continue to have symptoms even after treatment with a nasal steroid spray. The purpose of this study is to see if these patients are helped by adding another medication (montelukast) to their treatment compared to placebo (a substance that looks like the active medication but does not contain the drug).

Clinicians frequently prescribe an oral H1 antihistamine for allergic rhinitis patients with residual symptoms after taking an intranasal steroid. Surprisingly, the only studies investigating this combination of drugs have failed to show added efficacy of the H1 receptor over the intranasal steroids alone. Adding montelukast, a leukotriene receptor antagonist, to an intranasal steroid has not been studied in a placebo controlled fashion. Wilson and colleagues, in an open study of patients with chronic rhinosinusitis, showed a benefit of adding montelukast.

The investigators would like to recruit perennially allergic subjects and place them on fluticasone for 2 weeks. Those subjects with residual symptoms would then be randomized to receive either placebo or montelukast in addition to continuing the fluticasone for an additional 2 weeks.

A positive study would support clinical practice and would serve as a preemptive strike against managed care plans that would not allow prescriptions for both drugs.

Hypothesis:

The addition of montelukast to treatment of a perennially allergic subject with an intranasal steroid is more effective at relieving symptoms than a placebo.

Eligibility Criteria:
Inclusion Criteria:

* A clinical history of perennial allergic rhinitis and a positive skin prick test to dust mite, cockroach, mold, or cat or dog antigens.
* Willingness of the subject to participate in and complete the study, and the ability to understand the purpose of the trial.

Exclusion Criteria:

* Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.
* Women of childbearing potential who are pregnant, trying to become pregnant or nursing a child.
* Subjects treated with systemic steroids during the previous 30 days.
* Subjects treated with topical (inhaled, intranasal or intraocular) steroids, Nasalcrom or Opticrom during the previous 15 days.
* Subjects treated with oral antihistamines/decongestants during the previous seven days.
* Subjects treated with topical (intranasal or intraocular) antihistamines/decongestants during the previous 3 days.
* Subjects treated with immunotherapy who are escalating their dose.
* Subjects on chronic anti-asthma medications.
* Subjects with polyps in the nose or a significantly displaced septum.
* Subjects who have incurred an upper respiratory tract infection within 14 days of the start of the study.
An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical Practice

The objective of this survey on this registered product is to confirm the efficacy, and safety profile of Lantus in every day medical practice. This program will also help to obtain information about the use of the insulin titration regimen and handling of the Lantus insulin analogue.


Eligibility Criteria:
Inclusion Criteria:

* All newly diagnosed diabetics and existing diabetics uncontrolled on other anti-diabetic therapy, where treatment with basal insulin is required to control hyperglycaemia, and who the treating investigator considers may benefit from the treatment with Lantus, could enter in this program.

Exclusion Criteria:

-
Efficacy of Using Mobile Health Applications for Health

The purpose of this study is to determine the effectiveness of mobile health applications in improving health outcomes and type II diabetes outcomes in type 2 diabetics. This study will involve a 6-month long commitment where participants will be expected to weigh themselves every morning, at the same time, and check their blood glucose readings daily before and after meals for at least three meals in the day.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with type II diabetes for at least 3 months
* Between the age of 18-64
* BMI ≥ 25
* Monitors blood glucose regularly (at least once per day)
* Owns or has access to a bathroom weight scale
* Owns a smartphone and willing to download mobile app

Exclusion Criteria:

* Does not check blood glucose at least once per day
* On medications that promote weight gain such as antipsychotic, antidepressant, and steroid hormone medications.

Medications for diabetes such as insulin, thiazolidinediones or sulfonylureas are oka
The Role of Apathy in Glycemic Control

In spite of several new medications and insulins for the control of blood sugars in patients with diabetes, a large number of patients do not have good control. This likely due to inability to carry out regular activities and self-care behaviors such as taking meds regularly, keeping a good diet, exercise etc. This inability to carry out self care lifestyle changes may be due to a condition called apathy. Apathy is a lack of motivation and persistence. In this study we will attempt to treat apathy with a medication called methylphenidate for 6 months and see if blood sugar/diabetes control improves.

The incidence of diabetes in the US is at epidemic proportions. A large number of diabetes patients in the VA system have uncontrolled diabetes with high HbA1c. The inability to carry out important self-care behaviors such as measuring blood sugars regularly, following diet, exercise and medication programs may be due to apathy. Apathy is the lack of motivation, persistence and novelty. We have found this to be very prevalent in the VA diabetes population. We now do a randomized placebo controlled trial to see if treatment of apathy with methylphenidate will improve glycemic control in patients with A1c \>8. Treatment will be for 6 months. The primary end point is HbA1c.

Eligibility Criteria:
Inclusion Criteria:

* Poor glycemic control HbA1c\>8
* Presence of apathy, a score of \>30 on AES
* Subjects should be on stable dose of metformin, thiozolidinediones, and sulfonylureas, statins and ACE inhibitors for at least two months
* Subjects should have a negative cardiac stress test within the previous year

Exclusion Criteria:

* Presence of major depressive disorder, psychosis, suicidal ideations, and history of stimulant dependence as evaluated by MINI.
* Patient currently being treated or a history hypersensitivity to methylphenidate
* Hypertension with BP\>140/90
* History of renal disease with GFR\<60
* History of hepatic failure with AST/ALT \> three times the normal range
* History of seizure disorder, or Tourette's syndrome or presence of motor tics
* Patients with glaucoma
* Patients being treated with monoamine oxidase inhibitors (MAOIs) or Clonidine
* Patients with active cancer.
* Patients with acute illness needing hospitalization
* Patients with cardiovascular events such as myocardial infarction, stroke, amputation, unstable angina within the last six months.
* HbA1c\> 12
* Planned elective surgery in next 6 months
* Pregnancy
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.


Eligibility Criteria:
Inclusion Criteria:

1. The age of signing the informed consent is 18 -70 years, regardless of gender.
2. At least one measurable lesion according to RECIST v1.1 criteria.
3. The ECOG score is 0 or 1.
4. Expected survival ≥12 weeks.
5. Good level of organ function.
6. Have the ability to give informed consent and to comply with the treatment plan.
7. Male subjects whose partners are women of childbearing age and female subjects who are fertile are required to use highly effective contraceptive methods.

Exclusion Criteria:

1. Inadequately treated central nervous system metastases or the presence of uncontrolled or symptomatic active central nervous system metastases.
2. Spinal cord compression not cured by surgery and/or radiotherapy.
3. Subjects with uncontrolled tumor-related pain.
4. Received antitumor therapy within 4 weeks before the start of the study.
5. Subjects with severe cardiovascular and cerebrovascular disease.
6. History of immunodeficiency, including a positive HIV test.
Sirolimus in the Treatment of Refractory/Relapsed wAIHA

Autoimmune hemolytic anemia (AIHA) is a rare and heterogeneous disorder characterized by the destruction of red blood cells through warm or cold antibodies. Glucocorticoid (combined with rituximab) is the first-line treatment. However, the recurrence rate is very high and some patients may not respond to steroids. Second-line therapies include cyclosporine A (CsA), cyclophosphamide, rituximab, azathioprine, and even splenectomy. Our previous study of sirolimus in refractory/relapsed AIHA and ES found an effective rate of 80%. Therefore, the investigators plan to explore the efficacy and safety of sirolimus in the treatment of refractory/relapsed wAIHA.

Based on the optimal autoantibody-RBC reactivity temperatures, AIHA is classified into warm type, cold type, and mixed type. AIHA can be further classified into primary or secondary in nature. Glucocorticoid (combined with rituximab) is the first-line treatment. However, the recurrence rate is very high and some patients may not respond to steroids. Second-line therapies include cyclosporine A (CsA), cyclophosphamide, rituximab, azathioprine, and even splenectomy. The refractory/relapsed wAIHA patients have increased cardiovascular events, increased opportunities for infections, decreased quality of life, and even death. A prospective multi-institutional trial in autoimmune cytopenia found that 8 of 10 patients with AIHA and Evans syndrome respond to sirolimus. Our previous study of sirolimus in refractory/relapsed AIHA and ES also found an effective rate of approximately 80%. Since sirolimus is cheap and accessible, our findings may reduce the economic burden of patients and be a guide on the selection of second-line treatment drugs in refractory/relapsed wAIHA and Evans syndrome.

Eligibility Criteria:
Inclusion Criteria:

1. Age ≥18 years old.
2. Diagnosed as primary warm autoimmune hemolytic anemia or Evans syndrome (primary or secondary). There is no treatment indication of other systemic involvement in the original disease if secondary.
3. No response to glucocorticoid therapy or recurrence.
4. Baseline liver (ALT, AST) was less than 2 times the normal value.
5. No active infection; Not pregnant or breastfeeding.
6. Agree to sign the consent form.

Exclusion Criteria:

1. Patients with connective tissue disease or other organs involvement
2. Infection or bleeding that cannot be controlled by standard treatment.
3. Active HIV, HCV or HBV infection or cirrhosis or portal hypertension.
4. Progressed uncontrolled malignant tumors and lymphoma
5. Cirrhosis or portal hypertension.
6. Pregnant or breastfeeding.
Thrombophilia Screening After Severe IUGR

This retrospective study aims to assess the input of thrombophilia screening in pregnant women with severe intra-uterine growth restricted babies.


Eligibility Criteria:
Inclusion Criteria:

* Women over 18 years old
* Pregnant women
* IUGR defined by an EFW \<3rd centile
* IUGR before 25 GW

Exclusion Criteria:

* none